返回 Agendas
Using Registries to Support Recruitment in Alzheimer's Disease (AD) Prevention or Delay-of-Onset Studies
Session Chair(s)
Craig Metz, PhD
Senior Vice President
Black Swan Pharmaceuticals, United States
This session will present strategic considerations for using registries to recruit subjects for trials on delay of onset of mild cognitive impairment due to Alzheimer's Disease (AD), including development and regulatory issues and experience from an ongoing study.
Learning Objective : Describe strategic considerations for registry development or access; Evaluate how to satisfy HIPAA and regulatory requirements; Review data comparing and contrasting subject recruitment rates from sites with and without registries in an ongoing clinical trial evaluating delay of onset of mild cognitive impairment due to Alzheimer's disease (MCI due to AD).
Speaker(s)
Using the Brain Health Registry for Recruitment, Assessment and Longitudinal Monitoring in Alzheimer’s Clinical Trials
Rachel L. Nosheny, PhD
San Francisco VA Medical Center, United States
Research Scientist, Center for Imaging of Neurodegenerative Diseases
Cognitively Healthy Subject Registries for AD Delay of Onset Trials: The TOMMORROW Study Experience
Kathleen Anne Welsh-Bohmer, PhD
Duke University, United States
Professor
Ethical Considerations for Recruiting into Preclinical Alzheimer’s Trials from Subject Registries
Joshua Grill, PhD
University of California, Irvine, United States
Dept. of Psychiatry & Human Behavior, Institute for Memory & Neurological Disord
注册方法
Registration override should work.